ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference
Posters highlighting PRECISE-AD, the Company's Phase 1b clinical trial design and optimization of biomarkers in AD
Progress with trial enrollment following DSMB recommendation to proceed to second dose level
CAMBRIDGE, Massachusetts , July 29, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative diseases such as Alzheimer's Disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced it has been invited to present an overview of its ongoing PRECISE-AD trial in Alzheimer's Disease (AD) and its proprietary Discovery Platform, EpiSelectTM, at the Alzheimer's Association International Conference 2025 (AAIC) taking place in Toronto, Canada from July 27-31, 2025.
'We are pleased to share further details of our ongoing Phase 1b PRECISE-AD clinical trial evaluating PMN310, our novel therapeutic candidate for Alzheimer's disease,' said Dr. Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences. 'PRECISE-AD was intentionally designed with a robust framework to assess both the safety and potential signs of efficacy of PMN310. PMN310 is designed to selectively target toxic amyloid-beta oligomers, which are considered a primary driver of Alzheimer's disease, while aiming to reduce the risk of safety issues observed with other therapies. We were encouraged by the recent recommendation from the independent Data and Safety Monitoring Board (DSMB) to proceed to the second dose level, and we have been enrolling patients swiftly into this second cohort.'
'As of this week, more than 50% of the approximately 128 patients planned for the study have been enrolled, reflecting the pace of our clinical progress and the urgent need for new treatment options. To date, we have not observed any cases of amyloid-related imaging abnormalities (ARIA), including brain swelling or microhemorrhages. In addition, the U.S. Food and Drug Administration (FDA) recently granted Fast Track designation to PMN310, which we believe recognizes the potential of this program to address an unmet medical need in Alzheimer's disease. We anticipate reporting six-month interim data from the study in the second quarter of 2026, with topline results expected by the fourth quarter of 2026,' added Dr. Altstiel.
'The rapid enrollment in PRECISE-AD is a testament to the urgent need to bring new breakthroughs in treatment to Alzheimer's patients and providers,' Dr. David Watson, Chief Executive and Founder of the Alzheimer's Research and Treatment Center and one of the treating physicians in the PRECISE-AD trial stated. 'I am encouraged by the mechanism of ProMIS's PMN310, which has been designed to specifically target toxic Aβ oligomers, and has the potential to provide a more favorable product profile and significantly improve the quality of life of AD patients.'
'Additionally, we are pleased to have been invited to share data supporting the design process and validation of our proprietary target discovery engine, EpiSelectTM, which utilizes advanced computational discovery technologies to identify and target toxic misfolded proteins implicated in neurodegenerative and other misfolded protein diseases,' said Neil Cashman, M.D., Chief Scientific Officer and Co-founder, ProMIS Neurosciences. 'This precision targeting approach has enabled us to design novel therapeutic antibodies with a high degree of selectivity for the key underlying drivers of these conditions.'
Presentation details
Title: Protein misfolding-specific epitope identification for passive and active immunotherapy of neurodegenerative diseases
Presenter: Neil Cashman, M.D., Chief Scientific Officer and Co-founder, ProMIS Neurosciences
Session: Featured Research Session: Advancing Translational Success by Enhancing Predictive Validity in Neurodegenerative Diseases, Thursday, July 31, 2025: 10:00am – 11:30am Eastern Time
Abstract Number: 98670
Title: PRECISE-AD, A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients with Early Alzheimer's Disease
Presenter: Larry Altstiel, M.D., Ph.D., Chief Medical Officer, ProMIS Neurosciences
Session: In Person Poster: Drug Development: Human, Wednesday, July 30, 2025: 7:30am – 4:15pm Eastern Time
Poster Number: 103159
Title: Leveraging recent advances in biomarkers to optimize early phase drug development in Alzheimer's Disease
Joint Presenter: Garret Duncan, Statistician, Pentara Corporation and Johanne Kaplan, Ph.D., Chief Development Officer, ProMIS Neurosciences
Session: In Person Poster: Biomarkers: Biomarkers (non-neuroimaging), Monday, July 28, 2025: 7:30am – 4:15pm Eastern Time
Poster Number: 103841
Abstracts will be available on the
Poster and Publications
page of the Company's website at
www.promis
n
eurosciences.com
following the presentations.
About PMN310 and the PRECISE-AD Clinical Trial
PMN310, the Company's lead product candidate for the treatment of AD, is a humanized monoclonal antibody that has been designed to be differentiated in its ability to selectively target only the toxic oligomers, avoiding plaque, thereby potentially reducing or eliminating ARIA liability. In addition, because PMN310 may not be limited by off-target binding or side effects, PMN310 could potentially offer an improved efficacy profile over other amyloid-directed antibody therapeutics.
Based on the encouraging results from the Phase 1a trial (
NCT06105528
) of PMN310, ProMIS initiated PRECISE-AD, a Phase 1b clinical trial in AD patients. PRECISE-AD (
NCT06750432
) is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple ascending doses (5, 10, 20 mg/kg) of intravenous PMN310 in patients with Mild Cognitive Impairment due to AD and mild AD (Stage 3 and Stage 4 AD). PRECISE-AD will be the first study to examine the effects of a monoclonal antibody directed solely against AβO on biomarkers associated with AD pathology and clinical outcomes. Safety will be a primary outcome of the study with particular emphasis on assessing whether, as a non-plaque binder, PMN310 may have a reduced risk of ARIA. The study is powered to provide 95% confidence for detection of ARIA. The study has been designed with a sample size intended to provide sufficient power to provide meaningful insight into effects of PMN310 on biomarkers and clinical outcomes.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company's proprietary target discovery engine, EpiSelect™, predicts novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, 'forward-looking information') within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as 'plans', 'pleased to', 'look forward to', 'potential to', 'targets', 'expects' or 'does not expect', 'is expected', 'excited about', 'an opportunity exists', 'is positioned', 'estimates', 'intends', 'assumes', 'anticipates' or 'does not anticipate' or 'believes', or variations of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur' or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the Company's progress and expectations for its Phase 1b clinical trial in AD patients, including planned timing for completion and anticipated data readout of interim and full results in the second and fourth quarters of 2026, repsectively, the potential for such studies to provide the first proof-of-concept data for PMN310, the potential for PMN310 to positively benefit patients with AD and to be a more effective and well-tolerated option, the targeting of toxic misfolded proteins in neurodegenerative diseases that the Company believes may directly address fundamental AD pathology (including the belief and understanding that toxic oligomers of Aβ are a major driver of AD) and have greater therapeutic potential due to reduction of off-target activity and the Company's expectations regarding the benefits of Fast Track Designation and management's belief that its proprietary target discovery engine can predict and identify toxic misfolded proteins implicated in the development and progression of neurodegenerative and other misfolded protein diseases. Statements containing forward-looking information are not historical facts but instead represent management's current expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that enrollment may not continue at the current rate, that clinical results or early results may not be indicative of future results, the Company's ability to retain and recognize the incentives conferred by Fast Track Designation for PMN310, the Company's ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the 'Risk Factors' section of the Company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2024 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
For further information:
Visit us at
www.promisneurosciences.com
Please submit media inquiries to
info@promisneurosciences.com
For Investor Relations, please contact:
Kaytee Bock Zafereo
katherine.bock@promisneurosciences.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
2 hours ago
- Hamilton Spectator
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of July 31, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $30.54 per common share, which is equal to the closing price per share of Xenon's common shares on the grant date of July 31, 2025. The share option grants vest over four years, with 25% vesting on the one-year anniversary of the respective employee's start date and 1/36th of the remaining options vesting monthly thereafter on the last day of each month, subject to such option recipient's continued service relationship with the Company. Each option has a 10-year term and is subject to the terms and conditions of the share option agreement and the terms of the Company's 2025 Inducement Equity Incentive Plan. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit . 'Xenon' and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: For Investors: Chad Fugere Vice President, Investor Relations (857) 675-7275 investors@ For Media: Colleen Alabiso Senior Vice President, Corporate Affairs (617) 671-9238 media@
Hamilton Spectator
2 hours ago
- Hamilton Spectator
Lumine Group Inc. Announces Results for the Three and Six Months Ended June 30, 2025
TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) — Lumine Group Inc. ('Lumine Group' or 'the Company') (TSXV:LMN) announces financial results for the three and six months ended June 30, 2025. All amounts referred to in this press release are in US dollars unless otherwise stated. The following press release should be read in conjunction with the Company's unaudited condensed consolidated interim financial statements for the three and six months ended June 30, 2025, and management's discussion and analysis ('MD&A') for the three and six months ended June 30, 2025, which can be found on SEDAR+ at . Additional information about Lumine Group is also available on SEDAR+ and on Lumine Group's website . Q2 2025 Headlines: Year-to-Date Q2 2025 Headlines: Total revenue for the three months ended June 30, 2025 is $184.0 million, an increase of 13% or $21.1 million, compared to $162.8 million for the same period in 2024. For the six months ended June 30, 2025, total revenue was $362.6 million, an increase of 19%, or $58.7 million, compared to $303.9 million for the same period in 2024. The increase for the three and six months compared to the same period in the prior year is attributable to revenues from new acquisitions. The Company experienced organic growth of 9% and 2%, respectively, for the three and six months ended June 30, 2025, or 6% and 1% after adjusting for the impact of changes in the valuation of the US dollar against most major currencies in which the Company transacts business. For acquired companies, organic growth is calculated as the difference between actual revenues achieved by each business in the financial period following acquisition, compared to the estimated revenues they achieved in the corresponding financial period preceding the date of acquisition by the Company. Organic growth is not a standardized financial measure and might not be comparable to measures disclosed by other issuers. Operating income for the three months ended June 30, 2025 was $62.7 million, an increase of 71%, or $26.1 million, compared to $36.6 million for the same period in 2024. Operating income for the six months ended June 30, 2025 was $122.2 million, an increase of 51%, or $41.1 million, compared to $81.1 million for the same period in 2024. The increase for the three and six month periods is primarily attributable to growth from acquisitions. Operating income is not a standardized financial measure and might not be comparable to measures disclosed by other issuers. See 'Non-IFRS Measures'. Net income for the three months ended June 30, 2025 was $23.6 million compared to net loss of $2.2 million for the same period in 2024. Net income for the six months ended June 30, 2025 was $44.3 million compared to net loss of $306.6 million for the same period in 2024. The increase in net income for the three and six months is primarily attributable to growth from acquisitions and the Mandatory Conversion of Preferred and Special Securities on March 25, 2024 such that no further preferred and special securities expense was booked in the subsequent quarters. For the three months ended June 30, 2025, CFO increased $68.7 million to $78.4 million compared to $9.7 million for the same period in 2024 representing an increase of 705%. For the six months ended June 30, 2025, CFO increased $73.8 million to $118.5 million compared to $44.7 million for the same period in 2024 representing an increase of 165%. The primary reason for the increase is that CFO includes the impact of changes in non-cash operating assets and liabilities exclusive of effects of business combinations or changes in non-cash operating working capital ('NCOWC') which improved during the three and six months ended June 30, 2025 compared to the same period prior year, as well as higher operating income. For the three months ended June 30, 2025, FCFA2S increased $69.6 million to $72.4 million compared to $2.8 million for the same period in 2024. For the six months ended June 30, 2025, FCFA2S increased $75.8 million to $107.4 million compared to $31.5 million for the same period in 2024. The increase in the three and six months ended June 30, 2025 is driven by higher CFO compared to the same periods in 2024. FCFA2S is a non-IFRS Measure. See 'Non-IFRS Measures'. Non-IFRS Measures Operating income (loss) refers to income (loss) before income taxes, amortization of intangible assets, redeemable Preferred and Special Share expense, gain on bargain purchase, and finance and other expenses (income). We believe that operating income is useful supplemental information as it provides an indication of the profitability of the Company related to its core operations. Operating income (loss) is not a recognized measure under IFRS and may not be comparable to similar financial measures disclosed by other issuers. Accordingly, readers are cautioned that operating income (loss) should not be construed as an alternative to net income (loss). The following table reconciles operating income to net income: Free cash flow available to shareholders ''FCFA2S'' refers to net cash flows from operating activities less interest paid on lease obligations, interest paid on bank debt, transaction costs on bank debt, repayments of lease obligations, interest, dividends and other proceeds received, and property and equipment purchased net of proceeds from disposal. The Company believes that FCFA2S is useful supplemental information as it provides an indication of the uncommitted cash flow that is available to shareholders if Lumine Group does not make any acquisitions, or investments, and does not repay any debts. While the Company could use the FCFA2S to pay dividends or repurchase shares, the Company's objective is to invest all of its FCFA2S in acquisitions which meet the Company's hurdle rate. FCFA2S is not a recognized measure under IFRS and may not be comparable to similar financial measures disclosed by other issuers. Accordingly, readers are cautioned that FCFA2S should not be construed as an alternative to net cash flows from operating activities. The following table reconciles FCFA2S to net cash flows from operating activities: Forward Looking Statements Certain statements herein may be 'forward looking' statements that involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Lumine Group or the industry to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to vary significantly from the results discussed in the forward looking statements. These forward looking statements reflect current assumptions and expectations regarding future events and operating performance and are made as of the date hereof and Lumine Group assumes no obligation, except as required by law, to update any forward looking statements to reflect new events or circumstances. About Lumine Group Inc. Lumine Group acquires, strengthens, and grows, vertical market software businesses in the communications and media industry. Learn more at . For further information: David Nyland Chief Executive Officer Lumine Group investors@ +1-437-353-4910 Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Condensed Consolidated Interim Statements of Financial Position (In thousands of USD. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statements of Income (Loss) (In thousands of USD, except per share amounts. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statements of Comprehensive Income (Loss) (In thousands of USD. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statement of Changes in Equity (In thousands of USD. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statement of Changes in Equity (In thousands of USD. Due to rounding, numbers presented may not foot.) Condensed Consolidated Interim Statements of Cash Flows (In thousands of USD. Due to rounding, numbers presented may not foot.) 1 See 'Non-IFRS Measures'.
Business Upturn
4 hours ago
- Business Upturn
Local Marketing Plus SEO Expands Service Industry Solutions with Advanced SEO and Website Design in USA & Canada
Kelowna, Aug. 01, 2025 (GLOBE NEWSWIRE) — Local Marketing Plus SEO, a digital marketing agency specializing in boosting the online presence of diverse businesses, is excited to announce the expansion of its services for trades and service industries. This move underscores the company's dedication to offering customized solutions for businesses such as plumbers, electricians, renovation companies, and auto repair shops across the USA and Canada. With this expansion, the agency brings a full range of digital marketing services tailored to elevate the visibility of trades and service companies online. At the heart of these services is a refined SEO strategy that uses industry-specific insights to improve search engine rankings and increase organic website traffic. By using strategic keywords and optimizing digital positioning, Local Marketing Plus SEO helps its clients maintain a robust digital presence. Website design plays a significant role in the company's offerings, with packages ranging from bronze to platinum to fit various budgets. Each package ensures essential features like responsiveness and optimization, helping client websites look professional and work seamlessly on all devices. This approach not only enhances the user experience but also helps retain visitors. To learn more about their website design services, visit the Local Marketing Plus SEO website. 'We understand the particular challenges trades and service industries face in establishing a powerful online presence,' says Jo Ann McLellan, CEO of Local Marketing Plus SEO. 'Our objective is to empower these businesses with tools and strategies to stand out in a crowded digital market.' The agency is also expanding its AI virtual assistant offerings. Recognizing the need for automation in customer interactions, this service enhances scheduling, customer support, and lead conversion. As a result, businesses can manage daily operations more efficiently while boosting customer service standards. Information about the AI virtual assistant services is available on their site. In addition, Local Marketing Plus SEO provides Google Services, including the setup and optimization of Google My Business pages. This service is vital for ensuring businesses are prominently displayed in local searches, helping attract more nearby customers. Reputation management is another key service, assisting businesses in managing customer reviews and maintaining a positive online image. Jo Ann McLellan adds, 'Trades and service businesses have been a priority for us for years, and this expansion reaffirms our commitment to that sector. We've witnessed the positive impact of our strategies on our clients' ability to grow and sustain their operations, and we're thrilled to offer even more value with this initiative.' Local Marketing Plus SEO maintains an active social media presence, sharing insights and updates on its official LinkedIn page. Those interested can visit their website to learn more about the services available to improve their digital marketing strategies and online presence. For updates and more engagement, businesses can also follow Local Marketing Plus SEO's official LinkedIn page. By customizing its services to fit the unique needs of each client, Local Marketing Plus SEO remains a trusted partner for businesses looking to enhance their digital marketing efforts. The company's focus on staying ahead of industry trends while delivering effective strategies has cemented its reputation in the digital marketing field. Businesses hoping to boost their online engagement and expand their customer reach are encouraged to explore what Local Marketing Plus SEO offers. Visit or connect with their knowledgeable team for more details. ### For more information about Local Marketing Plus SEO, contact the company here: Local Marketing Plus SEOJo Ann McLellan1-800-330-5883 [email protected] Address: 347 Leon Ave #210, Kelowna, BC V1Y 8C7
